Flamingo Therapeutics Announces Poster Presentation on AML Phase 1 IIT Study at ASH 2024
Flamingo Therapeutics Announces Poster Presentation on AML Phase 1 IIT Study at ASH 2024
Title: "A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed by Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML"LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, Dec. 4, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced that an abstract has been selected for presentation at the 66th Annual ASH Annual Meeting and Exposition, being held in San Diego, CA from December 7-9, 2024.
比利時魯汶、法國斯特拉斯堡和費城，2024年12月4日 /PRNewswire/ -- Flamingo Therapeutics（"Flamingo"）今日宣佈，摘要已被選中在2024年12月7日至9日在加利福尼亞州聖地亞哥舉行的第66屆年會和博覽會上進行報告。
The abstract, selected for a poster presentation, is a Trials-in-Progress presentation of a Phase 1 investigator-initiated study of danvatirsen monotherapy followed by danvatirsen combination with venetoclax in relapsed/refractory AML and intermediate/high risk MDS (NCT05986240). The study is being conducted at Albert Einstein / Montefiore Medical Center in New York City and MD Anderson Cancer Center in Houston.
該摘要被選中進行海報展示，是對丹瓦替尼單藥治療隨後與維奈克拉克聯合治療復發/難治性急性髓系白血病（AML）和中度/高度風險骨髓增生異常綜合症（MDS）的階段1研究的進行中的報告（NCT05986240）。該研究在紐約市的阿爾伯特·愛因斯坦/蒙特菲奧裏醫療中心和休斯頓的MD安德森癌症中心進行。
Poster presentation details are as follows:
海報展示細節如下：
Title: "A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed by Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML"
Session Date: Monday, December 9, 2024
Presenting Author: Dr. Aditi Shastri
標題："一項研究丹瓦替尼的安全性和有效性的1期研究，作爲單藥治療隨後與維奈克拉克聯合治療復發/難治性MDS和AML患者"
會議日期：2024年12月9日星期一
報告作者：阿迪提·沙斯特里博士
For more information, please visit the ASH 2024 website.
欲了解更多信息，請訪問ASH 2024網站。
About Flamingo Therapeutics
關於Flamingo Therapeutics
Flamingo is pioneering RNA-targeted therapies for oncology with a clinical-stage pipeline targeting undruggable transcription factors and long non-coding RNAs. Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Abrdn (formerly funds managed by Tekla Capital Management LLC), Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, and VIB.
Flamingo正在開發針對腫瘤的RNA靶向療法，擁有一個針對不可藥物化轉錄因子和長非編碼RNA的臨床階段管線。Flamingo與 Ionis Pharmaceuticals 建立了聯盟，並得到了包括Abrdn（前Tekla資本管理公司管理的基金）、Andera Partners、Bpifrance大型風險投資、Bpifrance通過其FABS和Fonds Biothérapies Innovantes et Maladies Rares基金、Eurazeo - Kurma Partners、Perceptive Advisors、PMV、Pontifax、Sphera和VIb等知名生物技術投資者的支持。
Flamingo has initiated a Phase II trial 'PEMDA-HN' evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). A Phase I investigator initiated trial study has also been initiated evaluating danvatirsen as a monotherapy and in combination with venetoclax in AML/MDS patients.
Flamingo 已啓動 II 期臨床試驗 'PEMDA-HN'，評估 STAT3 靶向藥物 danvatirsen 與 pembrolizumab 聯合用於頭頸部鱗狀細胞癌 (HNSCC) 患者的療效。同時還啓動了一項 I 期調查者主導的臨床試驗，評估 danvatirsen 作爲單藥治療以及與 venetoclax 聯合用於 AML/MDS 患者的效果。
For more information on Flamingo, please visit:
有關Flamingo的更多信息，請訪問：
PEMDA-HN (head and neck cancer) on clinicaltrials.gov:
PEMDA-HN（頭頸癌）在clinicaltrials.gov上的信息：
Danvatirsen monotherapy followed by combination with venetoclax in relapsed/ refractory AML and MDS on clincaltrials.gov:
danvatirsen單藥治療後與venetoclax聯合治療復發/難治性AML和MDS在clinicaltrials.gov上的信息：
Please engage with us on LinkedIn:
.
請在LinkedIn上與我們互動：
.
Flamingo Media and Investor Contact:
Flamingo Media和投資者聯繫：
Amy Conrad
Juniper Point
(858) 366-3243
[email protected]
Amy Conrad
Juniper Point
(858) 366-3243
[email protected]
SOURCE Flamingo Therapeutics
來源 Flamingo Therapeutics
